PacBio Adds GeneDx, TychoBio Deals Alongside Q3 Revenue Growth and CFO Handoff
PACB has more than doubled off its 52-week low of $1.07.
Summary
PacBio's Q3 revenue came in at $40.6M, up 5.5% year over year, with an adjusted loss of $0.11 per share and GAAP gross margin down to 33% from 41%. The bigger new items are two partnerships: GeneDx will add PacBio's long-read whole-genome sequencing to its genome testing portfolio, and TychoBio will build full-length RNA datasets on HiFi and Kinnex for AI model training in RNA therapies. Those deals give the sequencing platform two commercial footholds beyond its own instruments. The CFO transition is now formalized — Jim Gibson stepped down, CEO Mark Van Oene is interim finance chief, and Bill Meyer was named chief accounting officer while a permanent CFO is sought. This follows the August guidance cut to $155M–$165M and the restructuring aimed at $30M–$40M in annual savings; the narrowed 2026 revenue range was reiterated with the Q3 release.
At the time of this announcement, PACB was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $792.6M. The 52-week trading range was $1.07 to $3.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.